awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33414307-4A3E0BF9-849B-4575-88AA-A045C7080817
Q33414307-4A3E0BF9-849B-4575-88AA-A045C7080817
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33414307-4A3E0BF9-849B-4575-88AA-A045C7080817
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
P2860
Q33414307-4A3E0BF9-849B-4575-88AA-A045C7080817
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33414307-4A3E0BF9-849B-4575-88AA-A045C7080817
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fcfc5d854116dc67e338ba12a3dfd2968f958be8
P2860
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.